Cargando…
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
BACKGROUND: Although p53 signature, benign-appearing epithelial cells with p53 diffuse expression, is frequently found in the fallopian tubes, the clinical and pathological significance of this lesion in the case of high-grade serous carcinoma (HGSC) patients still remains unclear. CASE PRESENTATION...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923005/ https://www.ncbi.nlm.nih.gov/pubmed/29703236 http://dx.doi.org/10.1186/s13000-018-0702-3 |
_version_ | 1783318266814398464 |
---|---|
author | Hatano, Yuichiro Fukuda, Shinya Makino, Hiroshi Tomita, Hiroyuki Morishige, Ken-ichirou Hara, Akira |
author_facet | Hatano, Yuichiro Fukuda, Shinya Makino, Hiroshi Tomita, Hiroyuki Morishige, Ken-ichirou Hara, Akira |
author_sort | Hatano, Yuichiro |
collection | PubMed |
description | BACKGROUND: Although p53 signature, benign-appearing epithelial cells with p53 diffuse expression, is frequently found in the fallopian tubes, the clinical and pathological significance of this lesion in the case of high-grade serous carcinoma (HGSC) patients still remains unclear. CASE PRESENTATION: A 56-year-old woman was referred to the gynecologist on account of abdominal distention. Since radiological and serological workup suggested that her illness was due to advanced ovarian cancer (FIGO Stage IVB), she received neoadjuvant chemotherapy, and the clinical evaluation of the chemotherapeutic response was a partial response. She underwent total hysterectomy with bilateral salpingo-oophorectomy, omentectomy, and intra-pelvic and para-aortic lymphadenectomy. Histologically, the cancer cells showed high-grade nuclear atypia and spread into the bilateral ovaries, omentum, uterine serosa, and left fallopian tube. The cancer cells showed complete absence of p53 but overexpressed p16, whereas some of benign-appearing tubal epithelial cells overexpressed p53 but lacked p16 expression. The results of direct sequence analysis revealed that the ovarian cancer contains a 1 bp deletion in exon 8 of TP53. Finally, the histological diagnosis of HGSC with discordant p53 signature was made. Interestingly, nuclear expression of γ-H2AX, a well-known marker of DNA damage, was not only observed in both p53 aberrantly-expressing lesions but also the benign-appearing tubal epithelium without p53 overexpression. After the histological confirmation, she received adjuvant chemotherapy and has been in disease-free condition without any detectable tumor for 5 months. CONCLUSION: Recent evidence suggests that p53 signature is the putative precursor of p53 overexpression-type HGSC. Because the putative precursors of the other p53 immunophenotypical HGSC are not proposed, we presume γ-H2AX-expressing cells without p53 overexpression may be a potent candidate of null-type TP53-mutated tubal cells, which are named “γ-H2AX responsive foci.” |
format | Online Article Text |
id | pubmed-5923005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59230052018-05-07 High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis Hatano, Yuichiro Fukuda, Shinya Makino, Hiroshi Tomita, Hiroyuki Morishige, Ken-ichirou Hara, Akira Diagn Pathol Case Report BACKGROUND: Although p53 signature, benign-appearing epithelial cells with p53 diffuse expression, is frequently found in the fallopian tubes, the clinical and pathological significance of this lesion in the case of high-grade serous carcinoma (HGSC) patients still remains unclear. CASE PRESENTATION: A 56-year-old woman was referred to the gynecologist on account of abdominal distention. Since radiological and serological workup suggested that her illness was due to advanced ovarian cancer (FIGO Stage IVB), she received neoadjuvant chemotherapy, and the clinical evaluation of the chemotherapeutic response was a partial response. She underwent total hysterectomy with bilateral salpingo-oophorectomy, omentectomy, and intra-pelvic and para-aortic lymphadenectomy. Histologically, the cancer cells showed high-grade nuclear atypia and spread into the bilateral ovaries, omentum, uterine serosa, and left fallopian tube. The cancer cells showed complete absence of p53 but overexpressed p16, whereas some of benign-appearing tubal epithelial cells overexpressed p53 but lacked p16 expression. The results of direct sequence analysis revealed that the ovarian cancer contains a 1 bp deletion in exon 8 of TP53. Finally, the histological diagnosis of HGSC with discordant p53 signature was made. Interestingly, nuclear expression of γ-H2AX, a well-known marker of DNA damage, was not only observed in both p53 aberrantly-expressing lesions but also the benign-appearing tubal epithelium without p53 overexpression. After the histological confirmation, she received adjuvant chemotherapy and has been in disease-free condition without any detectable tumor for 5 months. CONCLUSION: Recent evidence suggests that p53 signature is the putative precursor of p53 overexpression-type HGSC. Because the putative precursors of the other p53 immunophenotypical HGSC are not proposed, we presume γ-H2AX-expressing cells without p53 overexpression may be a potent candidate of null-type TP53-mutated tubal cells, which are named “γ-H2AX responsive foci.” BioMed Central 2018-04-27 /pmc/articles/PMC5923005/ /pubmed/29703236 http://dx.doi.org/10.1186/s13000-018-0702-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Hatano, Yuichiro Fukuda, Shinya Makino, Hiroshi Tomita, Hiroyuki Morishige, Ken-ichirou Hara, Akira High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis |
title | High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis |
title_full | High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis |
title_fullStr | High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis |
title_full_unstemmed | High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis |
title_short | High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis |
title_sort | high-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923005/ https://www.ncbi.nlm.nih.gov/pubmed/29703236 http://dx.doi.org/10.1186/s13000-018-0702-3 |
work_keys_str_mv | AT hatanoyuichiro highgradeserouscarcinomawithdiscordantp53signaturereportofacasewithnewinsightregardinghighgradeserouscarcinogenesis AT fukudashinya highgradeserouscarcinomawithdiscordantp53signaturereportofacasewithnewinsightregardinghighgradeserouscarcinogenesis AT makinohiroshi highgradeserouscarcinomawithdiscordantp53signaturereportofacasewithnewinsightregardinghighgradeserouscarcinogenesis AT tomitahiroyuki highgradeserouscarcinomawithdiscordantp53signaturereportofacasewithnewinsightregardinghighgradeserouscarcinogenesis AT morishigekenichirou highgradeserouscarcinomawithdiscordantp53signaturereportofacasewithnewinsightregardinghighgradeserouscarcinogenesis AT haraakira highgradeserouscarcinomawithdiscordantp53signaturereportofacasewithnewinsightregardinghighgradeserouscarcinogenesis |